Exenatide Affected Circulating Cardiovascular Risk Biomarkers Independently Of Changes In Body Composition
- Mathijs C. Bunck, MD (mcmbunck{at}vumc.nl)a,
- Michaela Diamant, MD, PhDa,
- B. Eliasson, MD, PhDd,
- A. Cornér, MDb,c,
- R.M. Shaginian, MDf,
- R.J. Heine, MD, PhD, FRCPa,e,
- M.-R. Taskinen, MD, PhDb,
- H. Yki-Järvinen, MD, PhD, FRCPb and
- U. Smith, MD, PhD, FRCPd
- aDepartment of Internal Medicine, Section of Endocrinology, Diabetes Center, VU University Medical Center, Amsterdam, the Netherlands
- bDepartment of Medicine, Helsinki University Central Hospital, Helsinki, Finland
- cMinerva Medical Research Institute, Helsinki, Finland
- dLundberg Laboratory for Diabetes Research, Sahlgrenska University Hospital, Goteborg, Sweden
- eEli Lilly and Company, Indianapolis, IN, United States
- fEli Lilly and Company, Houten, the Netherlands
Abstract
Objective To study the effect of exenatide (Ex) on body composition and circulating cardiovascular risk biomarkers.
Research Design and Methods Metformin-treated patients with T2D (N=69) were randomized to exenatide (Ex) or insulin glargine (IG) and treated for one-year. Body composition was evaluated by Dual-Energy X-ray Absorptiometry. Additionally, body weight, waist circumference and cardiovascular biomarkers were measured.
Results One-year treatment with Ex significantly reduced body weight, waist circumference, total body and trunkal fat mass by 6%, 5%, 11% and 13%, respectively. In addition, Ex increased total adiponectin by 12%, and reduced hsCRP by 61%. IG significantly reduced endothelin-1 by 7%. These changes were statistically independent of the change in total body fat mass and body weight.
Conclusions Ex treatment for 1 year reduced body fat mass and improved the profile of circulating biomarkers of cardiovascular risk. No significant changes were seen with IG except a trend for reduced endothelin-1 levels.
Footnotes
-
- Received December 25, 2009.
- Accepted April 20, 2010.
- Copyright © American Diabetes Association
